Education
About Us
Working with TipRanks
Follow Us
Cardiff Oncology, Inc. (CRDF)
NASDAQ:CRDF
Total Valuation
Cardiff Oncology has a market cap or net worth of $286.06M. The enterprise value is $47.41M.
Market Cap$286.06M
Enterprise Value$47.41M
Share Statistics
Cardiff Oncology has 66,525,856 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding66,525,856
Owned by Insiders3.57%
Owned by Institutions21.79%
Financial Efficiency
Cardiff Oncology’s return on equity (ROE) is -0.55 and return on invested capital (ROIC) is -57.56%.
Return on Equity (ROE)-0.55
Return on Assets (ROA)-0.47
Return on Invested Capital (ROIC)-57.56%
Return on Capital Employed (ROCE)-0.58
Revenue Per Employee21.34K
Profits Per Employee-1.42M
Employee Count32
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Cardiff Oncology is -4.55. Cardiff Oncology’s PEG ratio is <0.01.
PE Ratio-4.55
PS Ratio0.00
PB Ratio1.01
Price to Fair Value2.49
Price to FCF-0.56
Price to Operating Cash Flow-0.56
PEG Ratio<0.01
Income Statement
In the last 12 months, Cardiff Oncology had revenue of 683.00K and earned -45.43M in profits. Earnings per share was -0.95.
Revenue683.00K
Gross Profit279.00K
Operating Income-48.65M
Pretax Income-45.45M
Net Income-45.43M
EBITDA-48.25M
Earnings Per Share (EPS)-0.95
Cash Flow
In the last 12 months, operating cash flow was -42.75M and capital expenditures 0.00, giving a free cash flow of -42.75M billion.
Operating Cash Flow-42.75M
Free Cash Flow-42.75M
Free Cash Flow per Share-0.64
Dividends & Yields
Cardiff Oncology pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.97
52-Week Price Change30.85%
50-Day Moving Average2.98
200-Day Moving Average3.25
Relative Strength Index (RSI)63.67
Average Volume (3m)852.01K
Important Dates
Cardiff Oncology upcoming earnings date is Jul 31, 2025, TBA Not Confirmed.
Last Earnings DateMay 8, 2025
Next Earnings DateJul 31, 2025
Ex-Dividend Date―
Financial Position
Cardiff Oncology as a current ratio of 7.08, with Debt / Equity ratio of 23.62%
Current Ratio7.08
Quick Ratio7.08
Debt to Market Cap<0.01
Net Debt to EBITDA1.04
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Cardiff Oncology has paid -24.00K in taxes.
Income Tax-24.00K
Effective Tax Rate<0.01
Enterprise Valuation
Cardiff Oncology EV to EBITDA ratio is -3.25, with an EV/FCF ratio of -4.15.
EV to Sales229.65
EV to EBITDA-3.25
EV to Free Cash Flow-4.15
EV to Operating Cash Flow-4.16
Balance Sheet
Cardiff Oncology has $79.89M in cash and marketable securities with $1.36M in debt, giving a net cash position of -$78.53M billion.
Cash & Marketable Securities$79.89M
Total Debt$1.36M
Net Cash-$78.53M
Net Cash Per Share-$1.18
Tangible Book Value Per Share$1.74
Margins
Gross margin is -4456.01%, with operating margin of -7123.13%, and net profit margin of -6651.68%.
Gross Margin-4456.01%
Operating Margin-7123.13%
Pretax Margin-6655.20%
Net Profit Margin-6651.68%
EBITDA Margin-7063.98%
EBIT Margin-7123.13%
Analyst Forecast
The average price target for Cardiff Oncology is $13.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$13.00
Price Target Upside236.79% Upside
Analyst ConsensusStrong Buy
Analyst Count6
Revenue Growth Forecast-3.61%
EPS Growth Forecast-3.39%